Shares of Silo Pharma, Inc. (SILO) are surging more than 50% Friday morning after the company reported positive data for its drug candidate SPU-21 for the treatment of Arthritis.
The company today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents.
Silo Pharma said it is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).
SILO, currently at $5.21, has traded in the range of $0.17-$12.45 in the last 1 year.
Source: Read Full Article
Lates News:
-
Driving Bitcoin's Surge: MicroStrategy Founder on Education, Adoption, and Policy Impact
-
Heritage Insurance Drops 10% After Projecting Catastrophe Losses
-
AngloGold Ashanti Adds 6% On Decision To Invest $$$ In G2 Goldfields
-
Affirm Shares Ascend Following Deal With Walmart
-
65% Of Bitcoin Supply Unmoved In Over A Year, Signaling Bottom And Looming Upwards Price Action